Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant.
We report a case of a 49 year-old male who had undergone liver transplant due to hepatitis C, Laennec's cirrhosis, and hepatocellular carcinoma, and was treated with etanercept for recalcitrant generalized psoriasis. Clearance of psoriasis was achieved without any adverse effects or complications of his current conditions....

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection.
SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor. Anadys is currently enrolling...

ORASURE SUBMITS ORAQUICK HCV TEST PMA TO FDA.
OraSure Technologies, Inc. (NASDAQ: OSUR), Bethlehem, Penn., has submitted a pre-market approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for a rapid test for antibodies to the Hepatitis C virus ("HCV") utilizing OraSure Technologies' OraQuickR technology platform. When approved, the OraQuickR HCV test is expected to...

Sinovac Releases Statement on Healive Vaccine Suspension.
BEIJING, Dec. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading provider of vaccines in China, announced today that, the Health Services Bureau of Fengtai District in the City of Beijing suspended the use of 83 doses of inactivated hepatitis A vaccine Healive(R), following a report...

DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter.
PARSIPPANY, N.J. and LEIDEN, Netherlands, Nov. 25 /PRNewswire/ -- DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX), today announced that Hungary-based Gedeon Richter Plc. signed a commercial license agreement allowing Gedeon Richter to develop and produce...

Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference.
SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today that it will present at the 20th Annual Piper Jaffray Health Care Conference on Wednesday, December 3, 2008 at 9:30 a.m. EST (6:30 a.m. PST) at the New York Palace Hotel. Steve Worland, Ph.D., President and...

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies.
- Patent for Antibodies that Directly Bind to Phospholipid Targets Covers All Viral Infections and All Combination Regimens - - Patent Issuance Follows Nature Medicine Publication Confirming the Broad Anti-Viral Potential of Anti-Phospholipid Approaches - TUSTIN, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. ,...

Idenix Pharmaceuticals to Present at the PiperJaffray 20th Annual Health Care Conference.
CAMBRIDGE, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. announced today that Idenix management will participate in the PiperJaffray Annual Health Care Conference on Wednesday, December 3, 2008 at 4:30p.m. ET at The New York Palace Hotel in New York, NY. The live and archived webcast of...

Idenix Pharmaceuticals to Present at the PiperJaffray 20th Annual Health Care Conference.
CAMBRIDGE, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. announced today that Idenix management will participate in the PiperJaffray Annual Health Care Conference on Wednesday, December 3, 2008 at 11:30 a.m. ET (please note that the time of the presentation has changed) at The New York Palace Hotel in...

Ligand Collaborator GlaxoSmithKline Gets FDA OK for Promacta.
HEALTH AND BEAUTY CLOSE-UP-25 November 2008-Ligand Collaborator GlaxoSmithKline Gets FDA OK for Promacta(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Ligand Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of GlaxoSmithKline's (GSK) Promacta (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune...